Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Immix Biopharma Inc.
IMMX | US
9.69
USD0.43
4.64%
IMMX | US
About Immix Biopharma Inc.
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
13/04/2026
Close
9.69
Open
9.48
High
10.15
Low
9.24
Immix Biopharma Inc. a clinical-stage biopharmaceutical company engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111 a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120 a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles California.
View LessIMMX | US
Risk
100.6
Sharpe
5.72
Luna's Score
60/100
Recommendation
Hold
Luna says (IMMX | US)
What's Working
Low Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Strong Sharpe Ratio (> 1.2)
What's not Working
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
10 days
93.7%1 month
100.6%3 months
87.8%6 months
94.5%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
1.98
Debt to equity
0.05
Debt to assets
0.04
Ent. to EBITDA
-0.37
Ent. to rev.
-
PEG
-
Other Fundamentals
EBITDA
-20.18M
MarketCap
266.00M
MarketCap(USD)
266.00M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-103.81
Short ratio
6.35
Short perc.
6.44
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
2.15
Range1M
3.61
Range3M
7.43
Volumes: Market Activity
Rel. volume
0.69
Price X volume
5.83M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -0.37 | - | Cheaper |
| Ent. to Revenue | - | - | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 1.98 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 87.84 | - | Riskier |
| Debt to Equity | 0.05 | -1.23 | Expensive |
| Debt to Assets | 0.04 | 0.25 | Cheaper |
| Market Cap | 266.00M | - | Emerging |
